CHILLICOTHE, OH (March 10, 2021) – One in eight women will be diagnosed with invasive breast cancer in her lifetime; and the American Cancer Society says one in 39 women
Message :
Required fields
AVEO Oncology (Nasdaq:AVEO) today announced the appointment of Mike Ferraresso to chief commercial officer. Mr. Ferraresso will be responsible for managing AVEO’s commercial strategy and operations, including the commercialization of FOTIVDA
® (tivozanib). FOTIVDA is AVEO’s differentiated oral, once-daily, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) approved in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
“Directly on the heels of FOTIVDA’s approval, it is a pleasure to announce Mike’s appointment to chief commercial officer,” said Michael Bailey, president and chief executive officer of AVEO. “Mike’s hard work and dedication has played a crucial role in preparing for our evolution to a commercial organization. I look forward to working with Mike in his new role as we continue to execute
OSE Immunotherapeutics to Present New Data Reflecting Expansion and Progress on its Immuno-Oncology and Inflammation Preclinical Portfolio at the 2021 AACR Annual Meeting
Permanent Abstract Number: 1636
Title: Optimized antagonist anti-PD-1/IL-7 mutein bispecific antibody to sustain exhausted T cell function and to disarm Treg suppressive activity.
Morello A., Seité M., Durand J, Thépenier V., Teppaz G., Pengam S., Wilhelm E., Desselle A., Girault I., Mary C., Poirier N.
Session Type: E-Poster Session
Session Title: Therapeutic Antibodies
Title: Triggering the resolution of inflammation with agonistic anti-ChemR23 antibody dampens inflammation-driven carcinogenesis
Gauttier V., Lavy M., Trilleaud C., Biteau K., Girault I., Belarif L., Teppaz G., Mary C., Thepenier V., Blanquart C., Barillé-Nion S., Poirier N.
Henry Ford Cancer Institute launches new initiative to improve minority participation in clinical trials
Henry Ford Cancer Institute is launching the Participatory Action for Access to Clinical Trials (PAACT) project to dramatically improve the representation of the African American community and other minorities in cancer clinical trials.
Supported by a $750,000 grant from Genentech, PAACT is a community-based research initiative in collaboration with the Detroit Community-Academic Urban Research Center (Detroit URC) that will address various barriers to trust and participation in clinical trials. Researchers and community partners will focus on clinical trials involving breast, colorectal, lung, and prostate cancers, which are more likely to result in death for African Americans when compared to other racial and ethnic groups. The project is being implemented in partnership with community-based organizations and community leaders who are key stakeholders.
Champions Oncology, Inc.: Champions Oncology Reports Record Quarterly Revenue of $10.8 Million
HACKENSACK, NJ / ACCESSWIRE / March 11, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery and development through data-driven research strategies and innovative pharmacology, biomarker and data platforms, today announced its financial results for the third fiscal quarter ended January 31, 2021.
Third Quarter and Recent Highlights:
Delivered record quarterly revenue of $10.8 million, an increase of 20% year over year
Reported non-GAAP income from operations, excluding stock-based compensation, depreciation and amortization, of $1.3 million
Expanded Lumin Bioinformatics proprietary SaaS platform with proteomic module integration
Ronnie Morris, CEO of Champions, commented, We are pleased with our third quarter results and we continue to execute our long term strategy of investing in the developme